Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
502.00    -3.00 (-0.59%)
Bid:
501.50
Ask:
503.00
Spread: 1.50 (0.299%)
Market Cap: £2.22b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

11 Feb 2016 07:00

11 February 2016 – Tate & Lyle PLC

TRADING STATEMENT

Tate & Lyle issues the following trading statement for the three months ended 31 December 2015.

OPERATING PERFORMANCE – CONTINUING OPERATIONS

The Group remains on track to deliver full year guidance.

Speciality Food Ingredients performed steadily with volume ahead of the comparative period. Strong volume growth in Europe and Asia Pacific more than offset softer demand in North America and Latin America. In Food Systems, volume continued to grow and also benefited from the acquisition of Gemacom in December 2014, however margins declined as a result of the sharp increase in certain ingredient costs. SPLENDA® Sucralose volume was ahead of the comparative period although, as expected, pricing was lower year-on-year.

In Bulk Ingredients, North American sweetener volume in the quarter was slightly ahead of the comparative period. As previously communicated, the bulk sweetener pricing round will deliver modest margin gains in the fourth quarter. Commodities continue to have a material adverse impact on performance especially due to further weakness in the US ethanol market. As a result, we now expect a small loss from Commodities for the full year.

OUTLOOK

Our outlook for the full year remains unchanged. As previously communicated the Group’s adjusted profit before tax from continuing operations in constant currency and on an equity accounting basis is expected to be broadly in line with that of the 2015 financial year at £193 million1. At reported rates, adjusted profit before tax is expected to be modestly below this figure2.

The longer term outlook for the business remains positive. In Speciality Food Ingredients we expect the market to grow at mid-single digits, and over time our objective is to grow modestly ahead of the market and to drive margin expansion, supported by increased utilisation of new capacity, growing revenues from new products, and a gradual return to growth in North America. While in the near term we expect weakness in commodity markets to persist, we will continue to target stable earnings from core Bulk Ingredients and to manage Commodities to dampen volatility.

1 Guidance assumed foreign exchange rates of GBP: USD £1/US$1.54.2 Reflects the negative impact of non-US Dollar average exchange rates, principally the Mexican Peso and Brazilian Real.

END

A conference call will be held today at 8:00am GMT, hosted by Javed Ahmed, Chief Executive and Nick Hampton, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666Password: Tate & Lyle

UK replay number: +44 (0) 20 8196 1998Replay access PIN: 6063715#

A replay of this call will be available after the end of the live call for 14 days until 25 February 2016.

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor and Media RelationsTel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media RelationsTel: +44 (0) 203 727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations in over 30 locations worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2015, Tate & Lyle sales totalled £2.7 billion. For more information, please visit http://www.tateandlyle.com. SPLENDA® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160210006270/en/

Copyright Business Wire 2016

Date   Source Headline
4th Jun 20263:26 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
4th Jun 20263:25 pmRNSForm 8.3 - TATE & LYLE PLC
4th Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
4th Jun 20263:12 pmRNSForm 8.3 TATE & LYLE PLC
4th Jun 20262:45 pmRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
4th Jun 20262:45 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
4th Jun 20262:25 pmRNSForm 8.5 (EPT/NON-RI) - Tate & Lyle Plc
4th Jun 20262:23 pmRNSForm 8.3 - Tate & Lyle plc
4th Jun 20261:55 pmRNSForm 8.3 - Tate & Lyle plc
4th Jun 202612:57 pmRNSForm 8.3 - Tate & Lyle plc
4th Jun 202611:53 amRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
4th Jun 202611:32 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
4th Jun 202611:22 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
4th Jun 202611:19 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
4th Jun 202611:16 amRNS20260603_TATE & LYLE_8.5 EPT NON-RI_UK_BOFASE
4th Jun 202611:14 amRNS20260603_TATE & LYLE_8.5 EPT RI_UK_MLI
4th Jun 202610:59 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
4th Jun 202610:40 amRNSForm 8.3 - Tate & Lyle PLC
4th Jun 20269:25 amRNSForm 8.5 (EPT/RI)
3rd Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
3rd Jun 20263:16 pmRNSForm 8.3 TATE & LYLE PLC
3rd Jun 20262:25 pmRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
3rd Jun 20261:56 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
3rd Jun 20261:56 pmRNSForm 8.3 - Tate & Lyle plc
3rd Jun 20261:40 pmRNSForm 8.3 - Tate & Lyle plc
3rd Jun 202611:57 amRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
3rd Jun 202611:15 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
3rd Jun 202611:11 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
3rd Jun 202611:04 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
3rd Jun 202611:02 amRNS20260602_TATE & LYLE_8.5 EPT RI_UK_MLI
3rd Jun 202610:41 amRNSForm 8.3 - Tate & Lyle PLC
3rd Jun 202610:24 amRNSForm 8.5 (EPT/RI)
2nd Jun 20265:13 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
2nd Jun 20265:00 pmRNSForm 8.5 (EPT/NON-RI) - TATE & LYLE PLC
2nd Jun 20264:33 pmRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
2nd Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
2nd Jun 20263:00 pmRNSForm 8.3 TATE & LYLE PLC
2nd Jun 20262:47 pmRNSForm 8.5 (EPT/RI)-Amend Tate & Lyle PLC
2nd Jun 20262:30 pmRNSAnnual Financial Report and Notice of Meeting 2026
2nd Jun 202612:33 pmRNSForm 8.3 - Tate & Lyle PLC
2nd Jun 202611:47 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
2nd Jun 202611:45 amRNS20260601_TATE & LYLE_8.5 EPT RI_UK_MLI
2nd Jun 202611:44 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
2nd Jun 202611:32 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
2nd Jun 202611:04 amRNSForm 8.5 (EPT/RI)-Amend Tate & Lyle PLC
2nd Jun 20268:42 amRNSForm 8.5 (EPT/RI)
1st Jun 20265:27 pmRNS20260526_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement
1st Jun 20265:22 pmRNS20260526_TATELYLE8.5 EPT NON-RI BOFASE_replacement
1st Jun 20265:17 pmRNS20260522_TATE & LYLE_8.5 EPT RI_UK_MLI_replacement
1st Jun 20265:10 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.